

菅原正弘 院長 最近の主要な共著論文
(JAMA 等、欧米主要学会誌に掲載されています)

1) [Low-dose aspirin for primary prevention of cardiovascular events in Japanese patients 60 years or older with atherosclerotic risk factors: a randomized clinical trial.](#)

Ikeda Y, Shimada K, Teramoto T, Uchiyama S, Yamazaki T, Oikawa S, **Sugawara M**, Ando K, Murata M, Yokoyama K, Ishizuka N.

JAMA. 2014 Dec 17;312(23):2510–20.

2) [Febuxostat for Cerebral and Cardiovascular Events Prevention Study.](#)

Kojima S, Matsui K, Hiramitsu S, Hisatome I, Waki M, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Mori H, **Sugawara M**, Ohya Y, Kimura K, Saito Y, Ogawa H.

Eur Heart J. 2019 Jun 7;40(22):1778–1786.

3) [Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT \(Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus\) Study.](#)

Sasaki T, **Sugawara M**, Fukuda M.]

J Diabetes Investig. 2019 Jan;10(1):108–117.

4) [Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia.](#)

Kojima S, Matsui K, Ogawa H, Jinnouchi H, Hiramitsu S, Hayashi T, Yokota N, Kawai N, Tokutake E, Uchiyama K, **Sugawara M**, Kakuda H, Wakasa Y, Mori H, Hisatome I, Waki M, Ohya Y, Kimura K, Saito Y; Febuxostat for Cerebral and Cardiovascular Events Prevention Study (FREED) investigators.

J Cardiol. 2017 Jan;69(1):169–175.

□

5) [Efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes.](#)

Ohmura H, Mita T, Taneda Y, **Sugawara M**, Funayama H, Matsuoka J, Watada H, Daida H; SPIRITS-J Study Investigators.

J Clin Med Res. 2015 Apr;7(4):211–9.

6) Aspirin for Stroke Prevention in Elderly Patients With Vascular Risk Factors: Japanese Primary Prevention Project.

Uchiyama S, Ishizuka N, Shimada K, Teramoto T, Yamazaki T, Oikawa S, **Sugawara M**, Ando K, Murata M, Yokoyama K, Minematsu K, Matsumoto M, Ikeda Y; JPPP Study Group.

Stroke. 2016 Jun;47(6):1605–11.

7) Effects of daily aspirin on cancer incidence and mortality in the elderly Japanese.

Yokoyama K, Ishizuka N, Uemura N, Mizokami Y, Hiraishi H, Murata M, Uchiyama S, Teramoto T, Shimada K, Yamazaki T, Oikawa S, **Sugawara M**, Ando K, Ikeda Y; JPPP study group.

Res Pract Thromb Haemost. 2018 Apr 15;2(2):274–281.

8) Efficacy and safety of sitagliptin in elderly patients with type 2 diabetes mellitus: A focus on hypoglycemia.

Fukuda M, Doi K, **Sugawara M**, Mochizuki K.

J Diabetes Investig. 2019 Mar;10(2):383–391.

9) Intensive Treat-to-Target Statin Therapy in High-Risk Japanese Patients With Hypercholesterolemia and Diabetic Retinopathy: Report of a Randomized Study.

Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, **Sugawara M**, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators.

Diabetes Care. 2018 Jun;41(6):1275–1284.

10) Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Japanese Patients with Atherosclerotic Risk Factors: Subanalysis of a Randomized Clinical Trial (JPPP-70).

Sugawara M, Goto Y, Yamazaki T, Teramoto T, Oikawa S, Shimada K, Uchiyama S, Ando K, Ishizuka N, Murata M, Yokoyama K, Uemura Y, Ikeda Y; Japanese Primary Prevention Project (JPPP) Study Group.

Am J Cardiovasc Drugs. 2019 Jun;19(3):299–311.

11) [Influence of blood pressure on the effects of low-dose aspirin in elderly patients with multiple atherosclerotic risks.](#)

Ando K, Shimada K, Yamazaki T, Uchiyama S, Uemura Y, Ishizuka N, Teramoto T, Oikawa S, **Sugawara M**, Murata M, Yokoyama K, Ikeda Y; Japanese Primary Prevention Project (JPPP) Study Group.

J Hypertens. 2019 Jun;37(6):1301–1307.

12) [Achieving LDL cholesterol target levels <1.81 mmol/L may provide extra cardiovascular protection in patients at high risk: Exploratory analysis of the Standard Versus Intensive Statin Therapy for Patients with Hypercholesterolaemia and Diabetic Retinopathy study.](#)

Itoh H, Komuro I, Takeuchi M, Akasaka T, Daida H, Egashira Y, Fujita H, Higaki J, Hirata KI, Ishibashi S, Isshiki T, Ito S, Kashiwagi A, Kato S, Kitagawa K, Kitakaze M, Kitazono T, Kurabayashi M, Miyauchi K, Murakami T, Murohara T, Node K, Ogawa S, Saito Y, Seino Y, Shigeeda T, Shindo S, **Sugawara M**, Sugiyama S, Terauchi Y, Tsutsui H, Ueshima K, Utsunomiya K, Yamagishi M, Yamazaki T, Yo S, Yokote K, Yoshida K, Yoshimura M, Yoshimura N, Nakao K, Nagai R; EMPATHY Investigators.

Diabetes Obes Metab. 2019 Apr;21(4):791–800.

13) [Differences between rosuvastatin and atorvastatin in lipid-lowering action and effect on glucose metabolism in Japanese hypercholesterolemic patients with concurrent diabetes. Lipid-lowering with highly potent statins in hyperlipidemia with type 2 diabetes patients \(LISTEN\) study –.](#)

Ogawa H, Matsui K, Saito Y, Sugiyama S, Jinnouchi H, **Sugawara M**, Masuda I, Mori H, Waki M, Yoshiyama M, Watada H.

Circ J. 2014;78(10):2512–5.

14) [Effects of the N/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease \(J-CIRCLE study\).](#)

Uchida S, Takahashi M, **Sugawara M**, Saito T, Nakai K, Fujita M, Mochizuki K, Shin I, Morita T, Hikita T, Itakura H, Takahashi Y, Mizuno S, Ohno Y, Ito K, Ito T, Soma M. *J Clin Hypertens (Greenwich)*. 2014 Oct;16(10):746–53

15) [Optimal Combination of Effective ANtihypertensives \(OCEAN\) study: a prospective, randomized, open-label, blinded endpoint trial—rationale, design and results of a pilot study in Japan.](#)

Kageyama S, Ueda S, Mochizuki K, Miyakawa M, **Sugawara M**, Nakayama M, Ohashi Y, Saito I, Saruta T; OCEAN Study Group. *Hypertens Res*. 2012 Feb;35(2):221–7.

16) [\[Influence of physicians' subspecialty and training history on CKD management and medical cooperation: from the results of a nationwide questionnaire survey for primary care physicians\].](#)

Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, **Sugawara M**, Naka Y, Saruta T. *Nihon Jinzo Gakkai Shi*. 2013;55(8):1401–11.

17) [\[Current status of and regional differences in CKD management and medical cooperation in Japan: from the results of a nationwide questionnaire survey for primary care physicians\].](#)

Naito T, Ohtani H, Kobayashi K, Miyazaki M, Yamada K, **Sugawara M**, Naka Y, Saruta T. *Nihon Jinzo Gakkai Shi*. 2013;55(8):1391–400.

18) [The relationship between initial clinical manifestation and long-term prognosis of patients with systemic lupus erythematosus.](#)

Tokano Y, Morimoto S, Amano H, Kawanishi T, Yano T, Tomyo M, **Sugawara M**, Kobayashi S, Tsuda H, Takasaki Y, Hashimoto H. *Mod Rheumatol*. 2005;15(4):275–82.